Postantibiotic effects of garenoxacin (BMS-284756) against 12 gram-positive or -negative organisms

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 3, 2003, Pages 1140-1142

  Pankuch, G A ^a   Jacobs, M R ^b   Appelbaum, P C ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GARENOXACIN; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ARTICLE; DRUG EFFECT; ENTEROCOCCUS; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POSTANTIBIOTIC EFFECT; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; COLONY COUNT, MICROBIAL; CULTURE MEDIA; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; INDOLES; MICROBIAL SENSITIVITY TESTS; QUINOLONES; TIME FACTORS;

EID: 0037417054     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.3.1140-1142.2003     Document Type: Article

References (14)

1. Bassetti, M., L. M. Dembry, P. A. Farrel, D. A. Callan, and V. T. Andriole. 2002. Antimicrobial activities of BMS-284756 compared with those of fluoroquinolones and β-lactams against gram-positive clinical isolates. Antimicrob. Agents Chemother. 46:234-238.
2. Cars, O., and I. Odenholt-Tornqvist. 1993. The post-antibiotic sub-MIC effect in vitro and in vivo. J. Antimicrob. Chemother. 31:159-166.
3. Craig, W. 1993. Pharmacodynamics of antimicrobial agents as a basis for determining dosage regimens. Eur. J. Clin. Microbiol. Infect. Dis. 12(Suppl. 1):6-8.
4. Craig, W. A., and S. Gudmundsson. 1996. Postantibiotic effect, p. 296-329. In V. Lorian (ed.), Antibiotics in laboratory medicine. The Williams and Wilkins Co., Baltimore, Md.
5. Fix, A. M., M. A. Pfaller, D. J. Biedenbach, M. L. Beach, and R. N. Jones. 2001. Comparative antimicrobial spectrum of BMS284756 (T-3811, a desfluoroquinolone) tested against 656 Enterobacteriaceae, including preliminary in vitro susceptibility test comparisons and development. Diagn. Microbiol. Infect. Dis. 18:141-145.
6. Fung-Tomc, J., B. Minassian, B. Kolek, E. Huczko, L. Aleksunes, T. Stickle, T. Washo, E. Gradelski, L. Valera, and D. P. Bonner. 2000. Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS 284756. Antimicrob. Agents Chemother. 44:3351-3356.
7. MacKenzie, F. M., and I. M. Gould. 1993. The post-antibiotic effect. J. Antimicrob. Chemother. 32:519-537.
8. Murray, P. R., E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.). 1995. Manual of clinical microbiology, 7th ed. American Society for Microbiology, Washington, D.C.
9. National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed. Approved standard. NCCLS publication no. M7-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
10. Odenholt-Tornqvist, I. 1993. Studies on the postantibiotic effect and the postantibiotic sub-MIC effect of meropenem. J. Antimicrob. Chemother. 31:881-892.
11. Odenholt-Tornqvist, I., E. Löwdin, and O. Cars. 1992. Postantibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin, and amikacin. Antimicrob. Agents Chemother. 36:1852-1858.
12. Pankuch, G. A., K. Nagai, T. A. Davies, M. R. Jacobs, and P. C. Appelbaum. 2002. Antipneumococcal activity of BMS 284756 compared to those of six other agents. Antimicrob. Agents Chemother. 46:251-254.
13. Takahata, M., J. Mitsuyama, Y. Yamashiro, M. Yonezawa, H. Araki, Y. Todo, S. Minami, Y. Watanabe, and H. Narita. 1999. In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F-(6)-quinolone. Antimicrob. Agents Chemother. 43:1077-1084.
14. Wise, R., T. Gee, G. Marshall, and J. M. Andrews. 2002. Single-dose pharmacokinetics and penetration of BMS 284756 into an inflammatory exudate. Antimicrob. Agents Chemother. 46:242-244.